2016 Press Releases

Keyword Search
 
2016 | 2015 | 2014 | 2013 | 2012
DateTitle 
02/04/16Seattle Genetics Announces Commercial and Regulatory Progress under ADCETRIS® (Brentuximab Vedotin) Collaboration with Takeda
-$20 Million Milestone Payment Triggered by Annual ADCETRIS Net Sales Exceeding $200 Million in Takeda’s Territory During 2015- -European Commission Recently Approved a Type II Label Variation that Includes Data on the Retreatment of Relapsed or Refractory (R/R) Hodgkin lymphoma or R/R Systemic ALCL- BOTHELL, Wash.--(BUSINESS WIRE)--Feb. 4, 2016-- Seattle Genetics, Inc., (Nasdaq: SGEN) today announced that it will receive a one-time $2... 
Printer Friendly Version
01/20/16Seattle Genetics to Host Conference Call and Webcast Discussion of Fourth Quarter and Year 2015 Financial Results on February 9, 2016
BOTHELL, Wash.--(BUSINESS WIRE)--Jan. 20, 2016-- Seattle Genetics, Inc. (Nasdaq:SGEN) announced today that it will report its fourth quarter and year 2015 financial results on Tuesday, February 9 after the close of financial markets. Following the results announcement, company management will host a conference call and webcast discussion of the results and provide a general corporate update. Access to the event can be obtained as follows: ... 
Printer Friendly Version
01/05/16Seattle Genetics to Present at the J.P. Morgan Healthcare Conference
BOTHELL, Wash.--(BUSINESS WIRE)--Jan. 5, 2016-- Seattle Genetics, Inc. (NASDAQ:SGEN) announced today that Clay B. Siegall, Ph.D., President and Chief Executive Officer, will present at the 34th Annual J.P. Morgan Healthcare Conference on Monday, January 11, 2016 at 2:30 p.m. Pacific Time. Both the presentation and question and answer session that follows at 3:00 p.m. will be webcast live and available for replay from Seattle Genetics’ website at www.seat... 
Printer Friendly Version